The slow-eluting travoprost intracameral implant demonstrated statistical non-inferiority to timolol 0.5% eye drops and clinically relevant 8AM IOP-lowering efficacy at month 12.

The slow-eluting travoprost intracameral implant demonstrated statistical non-inferiority to timolol and clinically relevant IOP-lowering efficacy in mean diurnal IOP at all visits through month 12 at which diurnal IOP was prospectively collected.

Topical IOP-lowering medication burden was significantly reduced in eyes administered a slow-eluting travoprost intracameral implant, with 81.4% of eyes completely free of topical medication at month 12.

Slow-eluting travoprost intracameral implant demonstrated a favorable safety and tolerability profile.